Immunoglobulin Or Antibody Binds A Drug, Hapten, Hapten-carrier Complex, Or Specifically Identified Chemical Structure (e.g., Theophylline, Digoxin, Etc.) Patents (Class 435/345)
-
Publication number: 20110052608Abstract: The present invention relates to a novel antibody which selectively binds to the disease associated form of prion protein (PrPSc) under native conditions and the use thereof in methods of prion disease detection, therapy and disease research in general.Type: ApplicationFiled: June 13, 2007Publication date: March 3, 2011Applicant: UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGHInventors: Mark William Head, Michael Jones
-
Patent number: 7897733Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monoclonal antibody.Type: GrantFiled: November 14, 2005Date of Patent: March 1, 2011Assignee: Pfizer, Inc.Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain
-
Publication number: 20110020219Abstract: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.Type: ApplicationFiled: September 17, 2008Publication date: January 27, 2011Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHEInventors: De Santis Rita, Anastasi Anna Maria
-
Publication number: 20110014656Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.Type: ApplicationFiled: June 30, 2010Publication date: January 20, 2011Applicant: ZYMOGENETICS, INC.Inventors: STEVEN D. LEVIN, MARK W. RIXON, GAO ZEREN
-
Patent number: 7868142Abstract: It is intended to provide an anti-photocrosslinking group antibody capable of specifically binding to a photocrosslinking group and available in the binding of a substrate and a substance of interest in a microstructure, a complex protein including at least the antibody or at least a portion thereof, and a technique for use thereof in the detection of a target substance. The present invention provides a protein having at least the structure of an antibody that recognizes a photocrosslinking group.Type: GrantFiled: October 9, 2007Date of Patent: January 11, 2011Assignee: Canon Kabushiki KaishaInventors: Satoru Hatakeyama, Takeshi Imamura, Hidenori Shiotsuka
-
Publication number: 20100310597Abstract: A method that accurately and conveniently detects a compound shown by the formula (I) in a human sample is disclosed. An antibody that reacts with the compound shown by the formula (I), but does not cross-react with the N-oxide metabolite and the desmethyl levofloxacin metabolite of the compound shown by the formula (I) is prepared using an antigen produced by binding bovine serum albumin to the compound shown by the formula (I) through the 6-position carboxyl group. Immunoassay that measures the compound shown by the formula (I) that has not been metabolized is implemented using the above antibody.Type: ApplicationFiled: December 15, 2008Publication date: December 9, 2010Inventor: Osamu Miyazaki
-
Patent number: 7838215Abstract: Advanced cervical cancer screening methods that provide a molecular based process of detecting HPV-integration. The disclosed methods allow for a streamlined approach of conducting a Pap test and immunohistochemical test on the same slide. The disclosed methods provides an inexpensive, highly sensitive, specific, and detailed test that is easy to evaluate and follow-up.Type: GrantFiled: September 16, 2008Date of Patent: November 23, 2010Assignee: Canvir, Inc.Inventors: Peter Gombrich, Mitchell Golbus
-
Patent number: 7838245Abstract: The present invention relates to the use of protachykinin and/or fragments thereof that can be isolated from body fluids, tissues or other bioiological samples and therefore, serves as a marker peptide for medical diagnosis of diseases/disorders of the central nervous system, including Alzheimer's disease, Parkinson's disease, depression and/or conditions of pain, neurological, endocrinological, cerebral, muscular, local, systemic, chronic, inflammatory diseases, infectious diseases comprising bacterial and viral infections, meningitis, sepsis, Crohn's disease, colitis ulcerosa, sickle cell anemia, ischemia, amyotrophic lateral sclerosis, arthritis comprising rheumatoid arthritis, bronchitis, hyperalgesia, asthma, intoxication comprising bacterial intoxication, immunological disorders, poly/-trauma comprising cranio-cerebral trauma, tumors/cancer, stroke, stress, atopis dermatitis, HIV, Huntington's disease, burns, schizophrenia, Hirschsprung's disease, allergies, familial dysautononmia (Riley Day syndrome),Type: GrantFiled: April 20, 2005Date of Patent: November 23, 2010Assignee: Sphingotec GmbHInventors: Andreas Bergmann, Andrea Ernst
-
Patent number: 7794714Abstract: Anti-peptide monoclonal antibodies (MAb's) specific for Exotic Newcastle Disease (END) are used for rapid diagnostic identification between poultry infected with vaccine strains of NDV (LaSota/B1) and END virus (ENDV). Exotic Newcastle Disease is a contagious and fatal viral disease of birds and poultry. The present invention provides for diagnostic detection of ENDV in commercial poultry.Type: GrantFiled: March 14, 2008Date of Patent: September 14, 2010Assignee: The United States of America as represented by the Secretary of AgricultureInventor: Darrell R. Kapczynski
-
Patent number: 7763460Abstract: The invention provides methods for sensitive and specific detection of anti-HSV-2 antibodies by depletion of cross-reactive (non-specific) antibodies in a biological sample that can lead to a false positive result. The invention also features compositions, including nucleic acids, polypeptides, and kits, for use in the methods of the invention.Type: GrantFiled: December 6, 2005Date of Patent: July 27, 2010Assignee: Focus Diagnostics, Inc.Inventors: Xin Su, Lilly Kong, Wayne Hogrefe
-
Patent number: 7718425Abstract: The present invention relates to uses of a B-cell-depleting antibody for the treatment of a polyoma virus infection.Type: GrantFiled: May 2, 2007Date of Patent: May 18, 2010Assignee: Charité-Universit{umlaut over ( )}ätsmedizin BerlinInventors: Petra Reinke, Hans-Dieter Volk, Markus Hammer, Nina Babel, Gana Bold
-
Patent number: 7700744Abstract: The magnetic colloidal particles comprise a core and an envelope in which the core is magnetic and is coated with at least one polymer comprising functional groups X chosen from amine, hydroxyl, thiol, aldehyde, ester, anhydride, acid chloride, carbonate, carbamate, isocyanate and isothiocyanate groups, or mixtures thereof, at least one fraction of which has reacted with other functional groups of the envelope, and the envelope comprises a polymer bearing ionizable functional groups, Z and Z?, which may be identical or different, chosen from amine, carboxylic acid, ester, anhydride, aldehyde, thiol, disulfide, ?-halocarbonyl, sulfonic acid, maleimide, isocyanate and isothiocyanate groups, which have partially reacted with the functional groups X of the core. These magnetic colloidal particles can be used to isolate biological material.Type: GrantFiled: December 30, 2005Date of Patent: April 20, 2010Assignee: BiomerieuxInventors: Abdelhamid Elaissari, Bernard Mandrand, Thierry Delair, Doran Spencer, Ahmed Arkis
-
Publication number: 20100062542Abstract: It is intended to detect, concentrate and purify aflatoxins of all types which are possibly contained in a sample such as a food. It is also intended to detect the total amount or the individual amounts thereof at a high sensitivity. By using aflatoxin B2 or its derivative as a hapten compound, an antibody, which shows the same reactivity to individual aflatoxin analogs and is highly tolerant to organic solvents, is obtained. Then, a detection/concentration/purification means and an immunological detection means with the use of the above antibody are constructed. The detection means thus constructed achieves a high sensitivity and excellent quantification properties.Type: ApplicationFiled: November 13, 2007Publication date: March 11, 2010Inventors: Mikiko Uchigashima, Shiro Miyake, Hiroshi Yamashita
-
Publication number: 20090280128Abstract: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFN?. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFN?.Type: ApplicationFiled: December 20, 2006Publication date: November 12, 2009Inventors: Yumiko Kamogawa, Minkwon Cho, Naoko Arai, Koji Ishida
-
Publication number: 20090221066Abstract: The present invention provides a method of preparing an anti-methylated DNA antibody, comprising a step of administering to an animal an oligodeoxyribonucleotide containing a methylated cytosine(s) and an oligodeoxyribonucleotide containing no methylated cytosine. The antibody prepared by this method is capable of detecting a DNA containing a methylated cytosine(s) in a state close to the state of a biological component.Type: ApplicationFiled: March 27, 2007Publication date: September 3, 2009Inventors: Kunio Shiota, Shintaro Yagi, Fumiko Sunaga, Keiji Hirabayashi
-
Patent number: 7572456Abstract: The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.Type: GrantFiled: September 13, 2005Date of Patent: August 11, 2009Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang
-
Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs
Patent number: 7569676Abstract: The present invention comprises novel analogs of ecstasy-class compounds and novel ecstasy-class immunogens leashed out of, i.e., derived from, the methylenedioxy position. The invention also comprises unique monoclonal antibodies generated using MDO-leashed MDMA immunogens as well as unique conjugates and tracers. These antibodies, conjugates, and tracers are useful in immunoassays for the detection of ecstasy-class compounds in biological fluids.Type: GrantFiled: March 9, 2005Date of Patent: August 4, 2009Assignee: Roche Diagnostics Operations, Inc.Inventors: Mitali Ghoshal, Gerald F. Sigler, Richard Terry Root, Anlonga Ouyang, Salvatore J. Salamone -
Patent number: 7510838Abstract: Methods and compositions for identifying high-grade cervical disease in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in high-grade cervical disease. In particular claims, the body sample is a cervical smear or monolayer of cervical cells. The biomarkers of the invention include genes and proteins that are involved in cell cycle regulation, signal transduction, and DNA replication and transcription. In particular claims, the biomarker is an S-phase gene. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.Type: GrantFiled: September 14, 2006Date of Patent: March 31, 2009Assignee: TriPath Imaging, Inc.Inventors: Timothy J. Fischer, Douglas P. Malinowski, Adriann J. Taylor, Margaret R. Parker
-
Patent number: 7410642Abstract: Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed.Type: GrantFiled: April 17, 2006Date of Patent: August 12, 2008Assignee: Oklahoma Medical Research FoundationInventors: John B. Harley, Judith Ann James, Kenneth M. Kaufman
-
Patent number: 7408027Abstract: The invention relates to epitopes of the tau protein which are specifically occurring in a phosphorylated state in tau protein from Alzheimer paired helical filaments, to protein kinases which are responsible for the phosphorylation of the amino acids of the tau protein giving rise to said epitopes, and to antibodies specific for said epitopes. The invention further relates to pharmaceutical compositions for the treatment or prevention of Alzheimer's disease, to diagnostic compositions and methods for the detection of Alzheimer's disease and to the use of said epitopes for the generation of antibodies specifically detecting Alzheimer tau protein. Additionally, the invention relates to methods for testing drugs effective in dissolving Alzheimer paired helical filaments or preventing the formation thereof.Type: GrantFiled: August 17, 2000Date of Patent: August 5, 2008Assignee: Max-Planck-Gesellschaft zur Forderung der WissenchaftenInventors: Eva-Maria Mandelkow, Eckhard Mandelkow, Birgit Lichtenberg-Kraag, Jacek Biernat, Gerard Drewes, Barbara Steiner
-
Patent number: 7399467Abstract: The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.Type: GrantFiled: December 23, 2004Date of Patent: July 15, 2008Assignee: Arbor Vita CorporationInventors: Peter S. Lu, Jonathan David Garman, Michael P. Belmares, Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer
-
Patent number: 7384785Abstract: The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen suspected of being infected with WNV, JE, SLE or DEN with a substantially purified and isolated WNV E glycoprotein or subfragment thereof having a native conformation wherein the E glycoprotein or subfragment thereof has a reactivity with antibodies against WNV and a cross-reactivity with antibodies against JEV, SLEV and DENV. The instant invention further provides a rapid, sensitive, and consistent method for the specific detection of WNV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-WNV antibodies but not cross-reactive with antibodies against other flaviviruses such as JEV, SLEV, or DENV.Type: GrantFiled: May 4, 2004Date of Patent: June 10, 2008Assignee: Health Research, Inc.Inventors: Susan J. Wong, Pei-Yong Shi
-
Patent number: 7374756Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: GrantFiled: May 14, 2007Date of Patent: May 20, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Yoshiyasu Aoki, Giovanna Tosato
-
Patent number: 7371829Abstract: The invention provides haptens, immunogens comprising such haptens coupled to an antigenicity-conferring carrier material, conjugates comprising such haptens bonded to a labelling agent as well as, antibodies raised against such immunogens and capable of binding with ketamine and its primary metabolite, norketamine.Type: GrantFiled: January 31, 2003Date of Patent: May 13, 2008Assignee: Randox Laboratories LimitedInventors: Robert Ivan McConnell, Elouard Benchikh, Stephen Peter Fitzgerald, John Victor Lamont
-
Patent number: 7351554Abstract: A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine composition containing an active compound which is the native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or by adjuvant conditions; an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; a DNA molecule encoding the immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; or a DNA molecule encoding an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; along with an adjuvant of mucosal immunity.Type: GrantFiled: December 14, 2005Date of Patent: April 1, 2008Assignee: NeovacsInventor: Daniel Zagury
-
Patent number: 7335356Abstract: In this application are described Ebola GP monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of Ebola virus infections in vitro and in vivo.Type: GrantFiled: December 16, 2004Date of Patent: February 26, 2008Assignee: United States of America as represented by the Secretary of the ArmyInventors: Mary Kate Hart, Julie Wilson
-
Patent number: 7320861Abstract: A vaccine against disease caused by papilloma viruses is described in certain embodiments, as well as certain vectors, obtainable by the following methods: (a) one or more expression vectors that contain the DNA code for a structural protein of papilloma viruses or a fragment thereof are injected into mammals, whereby in at least some of the expression vectors randomly generated heterologous sequences are inserted into the DNA code (b) serums are obtained from the mammals and these are tested for the presence of antibodies against particles of various papilloma virus types, and (c) using the serums tested, the structural protein gene clones are identified that code for a polyvalent vaccine, and (d) the vaccine is produced from them. Procedures for producing a vaccine is also described, together with its use for vaccination against diseases caused by papilloma viruses.Type: GrantFiled: July 26, 2002Date of Patent: January 22, 2008Assignee: Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen RechtsInventors: Lutz Gissmann, Kai Pohlmeyer, Martin Müller
-
Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
Patent number: 7264802Abstract: The present invention provides a purified preparation containing, for example, at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), antigenic regions of such proteins which are at least 5 amino acids in length and which effectively protect a porcine host against a subsequent challenge with a PRRSV isolate, and combinations thereof in which amino acids non-essential for antigenicity may be conservatively substituted. The present invention also concerns a vaccine comprising an effective amount of such a protein; antibodies which specifically bind to such a protein; methods of producing the same; and methods of protecting a pig against a PRRSV, treating a pig infected by a PRRSV, and detecting PRRSV in a pig.Type: GrantFiled: March 25, 2002Date of Patent: September 4, 2007Assignee: Iowa State University Research FoundationInventors: Prem S. Paul, Yanjin Zhang -
Patent number: 7235365Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: GrantFiled: July 25, 2006Date of Patent: June 26, 2007Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Yoshiyasu Aoki, Giovanna Tosato
-
Patent number: 7157560Abstract: The present invention provides hapten derivatives useful for the preparation of antigens, antibodies and reagents for use in immunoassays for the detection of LSD and 2-oxo-3-hydroxy LSD. In the present invention, the 2-oxy LSD nucleus is derivatized out of the indole nitrogen to form an aminoalkyl derivative. The resulting haptens can then be further modified at this functionalized position for linking to appropriate immunogenic or labeling groups to provide reagents for immunoassays having substantially equal specificity for both LSD and 2-oxo-3-hydroxy-LSD.Type: GrantFiled: July 18, 2002Date of Patent: January 2, 2007Assignee: Roche Diagnostics Operations, Inc.Inventors: Mitali Ghoshal, Stephen Vitone, Gerald F. Sigler, Alan J. McNally
-
Patent number: 7157561Abstract: Activated haptens useful for generating immunogens to the HIV protease inhibitor atazanavir, immunogens useful for producing antibodies to atazanavir, and antibodies and labeled conjugates useful in immunoassays for determination of atazanavir. The haptens feature an activated functionality at the central, non-terminal hydroxyl group.Type: GrantFiled: November 5, 2004Date of Patent: January 2, 2007Assignee: Roche Diagnostics Operations, Inc.Inventors: Raymond A. Hui, Richard T. Root
-
Patent number: 7157233Abstract: Methods and compositions for identifying high-grade cervical disease in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in high-grade cervical disease. In particular claims, the body sample is a cervical smear or monolayer of cervical cells. The biomarkers of the invention include genes and proteins that are involved in cell cycle regulation, signal transduction, and DNA replication and transcription. In particular claims, the biomarker is an S-phase gene. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.Type: GrantFiled: March 23, 2005Date of Patent: January 2, 2007Assignee: TriPath Imaging, Inc.Inventors: Timothy J. Fischer, Douglas P. Malinowski, Adriann J. Taylor, Margaret R. Parker
-
Patent number: 7108981Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: GrantFiled: July 14, 2005Date of Patent: September 19, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Yoshiyasu Aoki, Giovanna Tosato
-
Patent number: 7105643Abstract: A monoclonal antibody, and a cell line capable of producing the same, has been produced with the ability to detect the primary metabolites generated from the pyrolysis of smokeable, or “crack”, cocaine. This monoclonal antibody, while being highly specific for anhydroecgonine methyl ester (AEME) and ecgonidine (ECD), does not cross-react at a significant level with the primary cocaine metabolites of powdered or injected cocaine. Also, crack cocaine conjugates capable of evoking an immune response in animals have been produced.Type: GrantFiled: July 30, 2003Date of Patent: September 12, 2006Assignee: The United States of America as represented by the Attorney General of the Dept. of JusticeInventor: Natalie T. Lu
-
Patent number: 7101980Abstract: Compounds including haptens, intermediates, and immunogens that are useful in the production of antibodies specific for the methylenedioxy class of amphetamine derivatives are described. Antibodies specific for the methylenedioxy class of amphetamine derivatives, reagent kits containing antibodies specific for the methylenedioxy class of amphetamine derivatives, methods of producing antibodies specific for the methylenedioxy class of amphetamine derivatives, and methods of detecting analytes including members of the methylenedioxy class of amphetamine derivatives are also described.Type: GrantFiled: July 18, 2003Date of Patent: September 5, 2006Assignee: Roche Diagnostics Operations, Inc.Inventors: Raymond A. Hui, Stephen Vitone, Richard Terry Root, Irina Baburina, Sheri Jordan
-
Patent number: 7090981Abstract: The present invention provides a new antigenic type of chicken anaemia viruses (CAV). The CAV according to this invention is isolatable from turkeys in the field and its virulence for chickens is significantly reduced. This property makes these viruses particularly suited for preparing a live vaccine for protecting poultry against disease conditions resulting from CAV infection.Type: GrantFiled: February 3, 2004Date of Patent: August 15, 2006Assignee: Akzo Nobel N.V.Inventors: Carla Christina Schrier, Henricus Johannes Maria Jagt
-
Patent number: 7070786Abstract: The present invention relates to at least one novel RSV proteins, antibodies, including isolated nucleic acids that encode at least one RSV protein or antibody, RSV vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: June 6, 2003Date of Patent: July 4, 2006Assignee: Centocor, Inc.Inventor: Bernard Scallon
-
Patent number: 7067258Abstract: The present invention relates to an immunoassay for simultaneously measuring the presence of antibodies to a plurality of HPV types that utilizes particle-based flow cytometric analysis. The presence and/or titre of neutralizing antibodies in a test sample are determined in a competitive format, where known, type-specific, fluorescently labeled neutralizing monoclonal antibodies compete with antibodies within a test sample for binding to conformationally sensitive, neutralizing epitopes on specific HPV-VLPs. The invention also provides a microsphere complex comprising a microsphere coupled to an HPV VLP.Type: GrantFiled: April 25, 2003Date of Patent: June 27, 2006Assignee: Merck & Co., Inc.Inventors: Mark T. Esser, David W. Opalka, Victor Goetz, James E. Drummond, Michael W. Washabaugh
-
Patent number: 7033797Abstract: The invention is a series of synthetic virus-like particles comprising a heterologous conformational epitope useful in the characterization of human papillomavirus infection, and useful to vaccinate individual for protection against HPV 6 and HPV 11 infections, and assays employing the synthetic virus-like particles.Type: GrantFiled: December 16, 2003Date of Patent: April 25, 2006Assignee: Merck & Co., Inc.Inventors: Kathrin U. Jansen, Jessica C. Ling, Steven W. Ludmerer, William L. McClements, Xin-Min Wang
-
Patent number: 6984492Abstract: A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.Type: GrantFiled: September 5, 2003Date of Patent: January 10, 2006Assignee: Talecris Biotherapeutics, Inc.Inventors: Ulrich Betz, Klaus-Peter Radtke
-
Patent number: 6967082Abstract: The present invention relates to a monoclonal antibody suitable for monitoring the activity of systems involving protein C inhibitor, a method for preparation of the monoclonal antibody, a method for monitoring the activity of systems involving protein C inhibitor and a method for diagnosis of e.g. venous thrombosis, wherein the monoclonal antibody is utilized. The monoclonal antibody is suitable for monitoring the activity of systems involving protein C inhibitor, and it has specific affinity for both i) a complex between a serine proteinase and an inhibitor thereof, and ii) a cleaved and uncomplexed form of the inhibitor, but has substantially no specific affinity for the inhibitor in its uncleaved and uncomplexed form; or a derivative thereof having the same biological activity.Type: GrantFiled: February 3, 2000Date of Patent: November 22, 2005Assignee: Forskarpatent I Syd ABInventor: Johan Stenflo
-
Patent number: 6942977Abstract: Methods are described for the development of monoclonal antibodies to intrinsic factor and the application of said antibodies in the development of B12 immunoassays. In particular, antibodies are described that are capable of binding to intrinsic factor only in the absence of vitamin B12, and that are released from binding in the presence, and upon the binding, of vitamin B12 to intrinsic factor. Assays may be formatted such that either antibody or intrinsic factor is immobilized or labeled.Type: GrantFiled: May 28, 1993Date of Patent: September 13, 2005Assignee: Bio-Rad Laboratories, Inc.Inventors: Karel Newman, Jane Schmidt, Paul Wegfahrt
-
Patent number: 6875433Abstract: In this application are described Ebola GP monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of Ebola virus infections in vitro and in vivo.Type: GrantFiled: August 23, 2002Date of Patent: April 5, 2005Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Mary Kate Hart, Julie Wilson
-
Patent number: 6866854Abstract: This invention provides an isolated nucleic acid which encodes a Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 2 polypeptide (LANA2) or a fragment thereof and also provides the LANA2 polypeptide. This invention provides an isolated nucleic acid comprising consecutive nucleotides having the sequence of a promoter of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 2 transcription. This invention also provides a method of inhibiting p53 mediated apoptosis of a cell and a method of producing an antibody which comprises introducing into a cell a replicable vector of the subject invention.Type: GrantFiled: September 5, 2003Date of Patent: March 15, 2005Assignee: The Trustees of Columbia University in the City of New YorkInventors: Yuan Chang, Patrick S. Moore
-
Patent number: 6843997Abstract: The present invention provides methods directed to detecting antibodies that specifically bind to a varicella zoster polypeptide, detecting the presence of a varicella zoster virus in an animal, diagnosing a disease caused by varicella zoster virus, and detecting a varicella zoster virus having a single nucleotide polymorphism in ORF68. The present invention also provides a vaccine composition, a method for producing a modified attenuated varicella zoster virus, isolated polynucleotides, and isolated polypeptides, and viruses.Type: GrantFiled: November 6, 2002Date of Patent: January 18, 2005Assignee: University of Iowa Research FoundationInventors: Charles F. Grose, Richard Santos
-
Patent number: 6803035Abstract: A food product and method for treating and preventing diarrhea in a subject animal suffering from or susceptible to diarrhea. The method comprises administering an egg product to the subject animal wherein the egg product is obtained from a hyperimmunized avian.Type: GrantFiled: January 22, 2002Date of Patent: October 12, 2004Assignee: Arkion Life SciencesInventors: Hellen Chaya Greenblatt, Orn Adalsteinsson, David A. Brodie, Henry Jacoby
-
Patent number: RE38824Abstract: A new human B lymphotropic virus, also designated human herpesvirus-6, has been isolated. DNA, molecular clones, antigenic viral proteins and antibodies having specificity to the new virus have been prepared. Various utilities of the new virus and products derived therefrom have been described.Type: GrantFiled: March 1, 2002Date of Patent: October 11, 2005Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Syed Z. Salahuddin, Dharam V. Ablashi, Steven F. Josephs, Carl W. Saxinger, Flossie Wong-Staal, Robert C. Gallo
-
Patent number: RE39544Abstract: A source of viral induced obesity has been discovered. A virus known as AD-36P adenovirus type 36 has been found to be associated with obesity in both animals and humans. Diagnostic DNA sequences are presented so that DNA based tests for the presence of the obesity associated virus can be conducted.Type: GrantFiled: April 6, 2005Date of Patent: April 3, 2007Assignee: Obetech, LLCInventors: Richard L. Atkinson, Nikhil V. Dhurandhar
-
Patent number: RE39914Abstract: A source of viral induced obesity has been discovered. A virus known as AD-36P adenovirus type 36 has been found to be associated with obesity in both animals and humans. Diagnostic DNA sequences are presented so that DNA based tests for the presence of the obesity associated virus can be conducted.Type: GrantFiled: June 27, 2006Date of Patent: November 6, 2007Assignee: Obetech, LLCInventors: Richard L. Atkinson, Nikhil V. Dhurandhar
-
Patent number: RE40832Abstract: A source of viral induced obesity has been discovered. A virus known as AD-36P adenovirus type 36 has been found to be associated with obesity in both animals and humans. Diagnostic DNA sequences are presented so that DNA based tests for the presence of the obesity associated virus can be conducted.Type: GrantFiled: October 5, 2007Date of Patent: July 7, 2009Assignee: Obetech, LLCInventors: Richard L. Atkinson, Nikhil V. Dhurandhar